NeuroMetrix to Present at the Digital Medicine Showcase 2017: At the Intersection of Technology and Medicine

WALTHAM, Mass.–(BUSINESS WIRE)–#chronicpain–NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) today announced that Shai N.
Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled
to speak at the Digital Medicine Showcase 2017 at the Parc 55 San
Francisco in San Francisco, CA. The Digital Medicine Showcase brings
together innovative companies showcasing clinically impactful digital
health technologies, venture capital and private equity investors,
pharma executives and professional advisors. Dr. Gozani will present the
Company’s Quell® Wearable Pain Relief Technology
on Wednesday, January 11, 2017, at 10:45 a.m. Pacific Time.

About Quell

Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can personalize and manage therapy discreetly
via the Quell Relief app. Quell also offers advanced health tracking
relevant to chronic pain sufferers including pain, sleep, activity, and
gait. Quell was the winner of the 2016 SXSW (South by Southwest)
Innovation Award for Best Wearable Technology. Quell is available at
select healthcare professionals and retailers. Visit QuellRelief.com
for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

Contacts

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com